BioNTech Charts New Course as Founders Depart and Cancer Drug Shows Promise

BioNTech reports strong Phase 2 endometrial cancer data for its ADC candidate, accelerating toward 2026 filing, while navigating post-COVID revenue decline and founder transition.

BioNTech SE finds itself at a pivotal crossroads. While its oncology pipeline delivered compelling clinical data over the weekend, the company is simultaneously navigating a profound leadership transition and a steep decline in its foundational COVID-19 business. This confluence of events presents investors with a complex narrative of long-term ambition tempered by near-term financial and operational headwinds.

The positive news stems from the SGO congress in Puerto Rico, where BioNTech presented Phase 2 results for its antibody-drug conjugate (ADC) candidate, trastuzumab pamirtecan (BNT323). In patients with advanced endometrial cancer, the therapy demonstrated an objective response rate of nearly 48%. For tumors with a particularly high HER2 expression, that efficacy figure jumped to over 73%, with a median progression-free survival of 8.1 months. These results, from the largest study of its kind for this specific cancer, underscore the drug's potential in an area with limited treatment options.

Building on this data and a previously granted FDA Fast Track designation, BioNTech is accelerating development. A global Phase 3 trial, which directly compares the monotherapy to standard chemotherapy, is already underway. The company, in partnership with DualityBio, now aims to file for formal regulatory approval in 2026. A separate catalyst is imminent: the Phase 3 trial for the same drug candidate in breast cancer is fully enrolled, with results expected later this year.

These clinical strides are critical as BioNTech's revenue from the Comirnaty COVID-19 vaccine continues to shrink. The company's financial guidance for 2026 projects revenue of just €2.0 to €2.3 billion, a significant drop from the nearly €2.9 billion booked in 2025. This declining income forces BioNTech to fund its substantial research expenditures from the cash reserves accumulated during the pandemic years. The commercial environment is further clouded by new FDA guidelines that recommend against annual boosters for most healthy adults under 65, a structural change likely to reduce the addressable market.

Investor sentiment reflects this challenging balance. BioNTech shares closed last Friday at €79.40, a daily gain of 2.12% but still down nearly 4% year-to-date and trading roughly 10% below their 200-day moving average.

Adding a layer of fundamental change is the impending departure of the company's visionary founders. Ugur Sahin and Özlem Türeci plan to step back from operational roles by the end of 2026 to establish a new, independent biotech firm focused on next-generation mRNA technologies. The supervisory board has initiated the search for their successors.

The upcoming virtual Annual General Meeting on May 15 will set the stage for this new chapter. Shareholders will vote on a strategic expansion of the supervisory board from six to eight members, with the explicit goal of adding two new specialists in oncology and clinical development. This governance shift precedes the company's first-quarter earnings report, scheduled for May 5, which will provide a clearer financial picture of how management is steering through these divergent currents.